Peptides · Peptide comparison
Pemvidutide vs Retatrutide
Balanced dual GLP-1/glucagon receptor agonist with no dose titration required and breakthrough therapy designation for MASH.
The world's first triple-action weight loss peptide that simultaneously activates three hormone receptors—GIP, GLP-1, and glucagon—delivering unprecedented weight loss results of up to 24% body weight in clinical trials [1][2].
- Weight Management
- Weight Management
At a glance
Quick comparison
Efficacy
Benefit ratings
Weight Loss
Liver Health
Metabolic Health
Weight Loss Power
Appetite Control
Technical data
Compound specifications
Pemvidutide
- Molecular formula
- C182H275N39O54
- Molecular weight
- 3873.35 Da
- Half-life
- Approximately 110 hours (4.6 days)
- Bioavailability
- Subcutaneous bioavailability consistent with glycolipid-conjugated peptide therapeutics
- CAS number
- 2538014-94-5
Retatrutide
- Molecular formula
- C221H342N46O68
- Molecular weight
- 4731 g/mol
- Half-life
- ~6 days (allows once-weekly dosing)
- Bioavailability
- High via subcutaneous injection
- CAS number
- 2381089-83-2
Protocols
Dosing compared
Pemvidutide
Subcutaneous
- 48 weeks1.2 mgOnce weekly · 48 weeksLowest dose studied; given at full strength from week 1 with no titration. Produced ~10% weight loss at 48 weeks in the MOMENTUM Phase 2 obesity trial [6] and is the lower MASH dose in the IMPACT Phase 2b trial [7].
- 48 weeks1.8 mgOnce weekly · 48 weeksMid dose, started at full strength with no titration; ~11% weight loss at 48 weeks (MOMENTUM) [6] and the higher MASH dose in IMPACT [7].
- 48 weeks2.4 mgOnce weekly · 48 weeksHighest dose; reached via a 4-week titration in MOMENTUM, where it produced 15.6% weight loss at 48 weeks [6].
Retatrutide
Subcutaneous
- Weeks 1-42 mgOnce weekly · Weeks 1-4 (then escalate 2 mg every 4 weeks)Phase 2 obesity trial initiated higher-dose arms at 2 mg weekly with stepwise 2 mg increases every 4 weeks to limit GI effects [1].
- Maintenance after titration4-8 mgOnce weekly · Maintenance after titrationMid-range maintenance doses; 8 mg produced ~22% mean weight loss at 48 weeks in the phase 2 trial [1][3].
- Maintenance (highest studied)12 mgOnce weekly · Maintenance (highest studied)Highest studied dose; produced ~24% mean weight reduction at 48 weeks [1]. Still investigational (not FDA-approved).
Applications
Best suited for
Pemvidutide
- Adults seeking substantial weight loss without complex dose titration
- Pemvidutide is particularly well-suited for individuals focused on adults seeking substantial weight loss without complex dose titration. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Individuals with concurrent MASH/NAFLD and obesity requiring dual-target therapy
- Pemvidutide is particularly well-suited for individuals focused on individuals with concurrent mash/nafld and obesity requiring dual-target therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][3].
- Patients with metabolic syndrome who need comprehensive risk factor improvement
- Pemvidutide is particularly well-suited for individuals focused on patients with metabolic syndrome who need comprehensive risk factor improvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Those interested in investigational dual agonist therapies with strong early data
- Pemvidutide is particularly well-suited for individuals focused on those interested in investigational dual agonist therapies with strong early data. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][3].
Retatrutide
- Significant Obesity Management
- If you need to lose a substantial amount of weight, retatrutide is showing unprecedented results. Phase 2 trials demonstrated average weight loss of 24% at the highest dose—that's nearly 60 pounds for someone weighing 250 lbs [1]. No other medication has matched this [1].
- Type 2 Diabetes with Obesity
- Retatrutide tackles both problems at once. It dramatically improves blood sugar control (HbA1c reductions of up to 2%) while delivering major weight loss [6]. The dual benefit makes it especially valuable for diabetics struggling with weight.
- Metabolic Syndrome Warriors
- If you're dealing with the cluster of issues that includes high blood sugar, excess belly fat, abnormal cholesterol, and high blood pressure, retatrutide's triple mechanism attacks multiple aspects of metabolic dysfunction simultaneously [5].
- Fatty Liver Disease (MASLD)
- Early research shows retatrutide may significantly reduce liver fat [7]. For people with non-alcoholic fatty liver disease, this peptide offers hope through weight loss plus direct metabolic improvements that benefit liver health.
Safety profile
Side effects
Pemvidutide
Common
- Nausea
- Diarrhea
- Headache
Uncommon
- Vomiting
- Decreased Appetite
Serious
- Acute Pancreatitis
- Severe Gastrointestinal Disturbance
Retatrutide
Common
- Nausea
- Diarrhea
- Constipation
- Decreased appetite
Uncommon
- Increased heart rate
- Injection site reactions
Serious
- Pancreatitis
- Gallbladder problems
Research status
Safety & evidence
Pemvidutide
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Research compound
- Safety overview
- Pemvidutide (ALT-801, developed by Altimmune; a GLP-1/glucagon dual agonist) [3][5] completed Phase IIb obesity trials with favorable cardiovascular safety profile. Gastrointestinal side effects (nausea, vomiting, diarrhea) occur in 30-40% of subjects, more prominent than GLP-1 monotherapy due to GCG receptor activation. Pancreatitis risk and elevated calcitonin levels require monitoring. No serious cardiac safety signals despite dual receptor activation; heart rate increases of 5-10 bpm observed.
Contraindications
- Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
- Known hypersensitivity to pemvidutide or formulation components
- History of acute pancreatitis
- Severe hepatic decompensation (Child-Pugh C cirrhosis)
Retatrutide
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Research compound
- Safety overview
- Retatrutide has shown a generally favorable safety profile in Phase 1 and Phase 2 clinical trials involving over 600 participants [1][6]. Most side effects are gastrointestinal and tend to improve over time [3]. The medication appears well-tolerated when doses are increased gradually. No major safety signals have emerged, but larger Phase 3 trials are still ongoing [3].
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Pregnancy or planning to become pregnant
- History of severe pancreatitis
- Known allergy to GLP-1 receptor agonists
Decision guide
Which is right for you?
Pemvidutide
Choose Pemvidutide if…
- Adults seeking substantial weight loss without complex dose titration
- Individuals with concurrent MASH/NAFLD and obesity requiring dual-target therapy
- Patients with metabolic syndrome who need comprehensive risk factor improvement
- Those interested in investigational dual agonist therapies with strong early data
Retatrutide
Choose Retatrutide if…
- Significant weight loss
- Type 2 diabetes management
- Metabolic health improvement
- Body composition optimization